volanesorsen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antisense oligonucleotides	5335	915430-78-3

Description:

Molecule	Description
Synonyms: volanesorsen volanesorsen sodium waylivra IONIS-304801 IONIS-APOCIII IONIS-APOCIIIRx	Volanesorsen is an antisense oligonucleotide designed to inhibit the formation of apoC-III, a protein that is recognised to regulate both triglyceride metabolism and hepatic clearance of chylomicrons and other triglyceride-rich lipoproteins. The selective binding of volanesorsen to the apoC-III messenger ribonucleic acid (mRNA) within the 3′ untranslated region at base position 489-508 causes the degradation of the mRNA. This binding prevents translation of the protein apoC-III, thus removing an inhibitor of triglyceride clearance and enabling metabolism through an LPL-independent pathway Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

volanesorsen
volanesorsen sodium
waylivra
IONIS-304801
IONIS-APOCIII
IONIS-APOCIIIRx

Volanesorsen is an antisense oligonucleotide designed to inhibit the formation of apoC-III, a protein that is recognised to regulate both triglyceride metabolism and hepatic clearance of chylomicrons and other triglyceride-rich lipoproteins. The selective binding of volanesorsen to the apoC-III messenger ribonucleic acid (mRNA) within the 3′ untranslated region at base position 489-508 causes the degradation of the mRNA. This binding prevents translation of the protein apoC-III, thus removing an inhibitor of triglyceride clearance and enabling metabolism through an LPL-independent pathway

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
20	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 3, 2019	EMA	Akcea Therapeutics Ireland Limited

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AX18	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Other lipid modifying agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chylomicronemia syndrome	indication	402786009
Thrombocytopenic disorder	contraindication	302215000	DOID:1588

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
apolipoprotein C-III (apoC-III) mRNA	RNA	P02656	APOC3_HUMAN	ANTISENSE INHIBITOR				UNKNOWN	DRUG LABEL

External reference:

ID	Source
2O4BE0K238	UNII
1573402-50-2	SECONDARY_CAS_RN
C4726970	UMLSCUI
CHEMBL3544994	ChEMBL_ID
121494123	PUBCHEM_CID
DB15067	DRUGBANK_ID
CHEMBL3544989	ChEMBL_ID
10166	INN_ID
8681	IUPHAR_LIGAND_ID
018803	NDDF
018804	NDDF
2637345	RXNORM
37541	MMSL
C000593612	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

None